trending Market Intelligence /marketintelligence/en/news-insights/trending/goqfrw62x1dsozbddgd9va2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Genscript Biotech to invest $75M in China biologics center


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Genscript Biotech to invest $75M in China biologics center

Genscript Biotech Corp. plans to invest $75 million to set up a biologics clinical and commercial manufacturing center in Zhenjiang, China.

The company intends to use the facility for the production of clinical samples and commercialized biologics. The facility will include areas for the production, filling, quality control and cold chain logistics for biologics, warehouse facilities for raw and auxiliary materials, energy center and other purposes.

Genscript said the facility would allow for phases 1 to 3 clinical sample production and commercial production to meet local and foreign client demands. The total production capacity of the manufacturing center is estimated to reach 5,700 liters.

Jiangsu, China-based Genscript makes and sells life sciences research products and services.